Ziihera: Dosage Form, Projected Sales, NCE-1 Date | Zanidatamab-Hrii

Ziihera

Ziihera is the first and only approved bispecific antibody drug. It treats unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer. This drug is given to patients who have already received the other chemotherapeutic treatment.

The information outlined in the molecule details section below would help you plan aBLA development early to enable a streamlined and competitive biosimilar strategy.

Molecule Details :

Molecule Name :

Zanidatamab-Hrii
Innovator :

JAZZ PHARMACEUTICALS
Approval Date :

20-Nov-24
Data Exclusivity Expiry :

20-Nov-28
Market Exclusivity Expiry :

20-Nov-36
Dosage Form :

Intravenous Infusion
Strength :

30mg/vial
Therapeutic Category :

Anticancer
Revenue ($M) :

1

Year-wise Projected Sales ($M) :

2025 :

29
2026 :

92
2027 :

235
2028 :

376
2029 :

555
2030 :

790
2031 :

981

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Ziihera

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?